NEW YORK (GenomeWeb) – Repositive and AstraZeneca this week named the inaugural members of the PDX Consortium, a group that was set up with the aim of developing a collaborative, pre-competitive resource of molecular data from patient-derived xenografts (PDXs) for use in oncology research. Inaugural members include AstraZeneca, Boehringer Ingelheim, Merck Group, Xentech, Xenopat, and Horizon Discovery.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.